Please login to the form below

Not currently logged in
Email:
Password:

TEVA-48125

This page shows the latest TEVA-48125 news and features for those working in and with pharma, biotech and healthcare.

Teva says chronic migraine drug is ready for phase III

Teva says chronic migraine drug is ready for phase III

TEV-48125 efficacy “has not previously been achieved”.  . Teva's novel migraine drug TEV-48125 should start phase III trials shortly, after showing 'unprecedented' activity in a mid-stage study, says ... year. The efficacy shown by TEV-48125 "has

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics